URL has been copied successfully!
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
- Stifel analyst Dara Azar initiated coverage on Inhibrx Biosciences Inc (NASDAQ:INBX) with a Buy rating and announced a price target of $150. Inhibrx Biosciences shares closed at $62.35 on Tuesday. See how other analysts view this stock.
- Needham analyst Ami Fadia initiated coverage on MapLight Therapeutics Inc (NASDAQ:
Please follow us:
This post was originally published here
